- Zacks
Bristol Myers' (BMY) Krazati Gets FDA Nod for Colorectal Cancer
Bristol Myers (BMY) wins FDA approval for Krazati, in combination with Erbitux, as a targeted treatment option for adult patients with KRASG12C-mutated locally advanced or metastatic colorectal cancer.
- Zacks
Roche (RHHBY), Ascidian Team Up for RNA Exon Editing Therapeutics
Roche (RHHBY) gets exclusive, target-specific rights to Ascidian's RNA exon editing technology for undisclosed neurological targets for an initial payment of $42 million.
- Zacks
Terns (TERN) Gains 13.6% YTD: Will the Momentum Continue?
Terns Pharmaceuticals, Inc. (TERN) outperforms the industry year to date on encouraging pipeline progress of its oncology candidate.
© 2024 Yahoo. All rights reserved.